Document Detail


Influence on quality of life from an early cinacalcet prescription for secondary hyperparathyroidism in dialysis.
MedLine Citation:
PMID:  25111639     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVE: The goal of this study is to compare patient-reported quality of life (PRQOL) evolution between two groups of end-stage renal disease patients with secondary hyperparathyroidism (SHPT). The first with a cinacalcet prescription within 3 months after a diagnosis of SHPT (early group) and a second group of patients with a later or no cinacalcet prescription (nonearly group).
PATIENTS AND METHODS: From 2009 to 2012, we conducted a multicenter pharmaco-epidemiologic study in Lorraine region (France) including all consecutive patients on maintenance dialysis for at least 3 months with a diagnosis of SHPT (PTH > 500 pg/ml or first cinacalcet prescription). PRQOL was estimated using the Kidney Disease Quality Of Life-Short Form questionnaire, at baseline and at 6 and 12 months follow-up. Change in PRQOL was compared between the groups and adjusted with a propensity score.
RESULTS: We included 124 patients: 44 in the early group and 80 in the nonearly group. The mental component summary score was lower in the early group, at baseline (43.6 ± 6.6 vs 46.6 ± 7.6; p = 0.030), and at the follow-up assessment (42.6 ± 6.9 vs 45.7 ± 7.9; p = 0.033). We found no difference between the groups in change in PRQOL, for all dimensions, even after adjustment with the propensity score. Mean serum alkaline phosphatase levels were normal in both groups at baseline (80.9 ± 32.5 vs 95.1 ± 39.6; p = 0.41).
CONCLUSION: Cinacalcet prescription immediately following diagnosis of SHPT does not seem to be associated with better PRQOL evolution at 1 year. Mean serum alkaline phosphatase levels suggest that physicians should consider waiting for another PTH assay result before starting cinacalcet in case of a PTH rise. Copyright © 2014 John Wiley & Sons, Ltd.
Authors:
Pierre Filipozzi; Carole Ayav; Marie-Line Erpelding; Michèle Kessler; Laurent Brunaud; Luc Frimat
Related Documents :
25106879 - Arthroscopy for mechanical symptoms in osteoarthritis: a cost-effective procedure.
7110819 - Persistent neonatal hypoglycemia due to hyperinsulinism: medical aspects.
19198989 - How much of the pancreatic head should we resect in frey's procedure?
23680969 - The randomized shortened dental arch study: oral health-related quality of life.
17534689 - Long-term outcome after resection for chronic pancreatitis in 224 patients.
24802769 - Adaptive compression therapy for venous leg ulcers: a clinically effective, patient-cen...
25484599 - Can orthopedic oncologists predict functional outcome in patients with sarcoma after li...
23413799 - Comparison of clinical and laboratory findings in early- and late- onset preeclampsia.
21088379 - The karyology of uraeotyphlus gansi, and its implications for the systematics and evolu...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-8-11
Journal Detail:
Title:  Pharmacoepidemiology and drug safety     Volume:  -     ISSN:  1099-1557     ISO Abbreviation:  Pharmacoepidemiol Drug Saf     Publication Date:  2014 Aug 
Date Detail:
Created Date:  2014-8-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9208369     Medline TA:  Pharmacoepidemiol Drug Saf     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014 John Wiley & Sons, Ltd.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The first case of a patient with de novo partial distal 16q tetrasomy and a data's review.
Next Document:  Ventilatory Strategies in Severe Acute Respiratory Failure.